Physician profile

Laura Stephens

Family · Birmingham, AL

NPI 1710314208

$447.12

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$211.73

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Astellas Pharma US INC $154.36 2022-2024 Cresemba
Rigel Pharmaceuticals, INC. $99.22 2023 Tavalisse, Rezlidhia
Abbvie INC. $51.15 2022-2023
Astrazeneca Pharmaceuticals LP $26.96 2024 Imfinzi
Abbott Laboratories $24.67 2022
Janssen Biotech, INC. $24.40 2022
Genzyme Corporation $23.59 2021
Puma Biotechnology, INC. $21.76 2023 Nerlynx
Kite Pharma, INC. $21.01 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Laura Stephens

$447.12

in general payments reported 2019-2025

Years
2021-2024
Top company
Astellas Pharma US INC

https://glasscript.com/doctor/10816533/laura-stephens

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.